Clinical Focus ›› 2022, Vol. 37 ›› Issue (12): 1081-1088.doi: 10.3969/j.issn.1004-583X.2022.12.003
Previous Articles Next Articles
Wang Lingling, Wu Jinlan, Wu Wei, Shen Shipeng, Chi Yanqing, Liu Maodong()
Received:
2022-08-12
Online:
2022-12-20
Published:
2023-01-18
Contact:
Liu Maodong
E-mail:lmdgxh@126.com
CLC Number:
Wang Lingling, Wu Jinlan, Wu Wei, Shen Shipeng, Chi Yanqing, Liu Maodong. A meta-analysis of the renal protective effects of vitamin D and its analogues in non dialysis patients with chronic kidney disease[J]. Clinical Focus, 2022, 37(12): 1081-1088.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.12.003
研究 | 国家 | 周期 (周) | 干预措施 | 样本量 | 平均年龄 (岁) | 收缩压 (mmHg) | 舒张压 (mmHg) | 结局指标 |
---|---|---|---|---|---|---|---|---|
Alborzi等[ | 美国 | 6 | 空白对照 | 8 | 68.4 | 未描述 | 未描述 | ①③ |
帕立骨化醇(1 μg/d) | 8 | 72.6 | ||||||
帕立骨化醇(2 μg/d) | 8 | 67.5 | ||||||
Fishbane等[ | 美国 | 24 | 安慰剂 | 27 | 60.8 | 未描述 | 未描述 | ①⑤⑥⑦ |
帕立骨化醇 | 28 | 55.0 | ||||||
de Zeeuw等[ | 美国 | 24 | 安慰剂 | 93 | 64.0 | 142.0 | 73.0 | ① |
帕立骨化醇(1 μug/d) | 93 | 64.0 | 142.0 | 73.0 | ||||
帕立骨化醇(2 μg/d) | 95 | 65.0 | 141.0 | 73.0 | ||||
Liu等[ | 中国 | 48 | 空白对照 | 24 | 36.3 | 118.3 | 73.8 | ②⑤⑥ |
骨化三醇 | 26 | 35.6 | 117.1 | 76.7 | ||||
殷勋等[ | 中国 | 24 | 缬沙坦 | 20 | 66.5 | 111.8 | 71.3 | ②⑤⑥⑦ |
骨化三醇 | 20 | 68.8 | 110.2 | 69.1 | ||||
Molina等[ | 西班牙 | 24 | 空白对照 | 51 | 67.4 | 130.5 | 72.8 | ①③④⑤⑥⑦ |
24 | 胆钙化醇 | 50 | 77.3 | 133.7 | 72.7 | |||
Wu等[ | 中国 | 24 | 空白对照 | 32 | 56.1 | 134.0 | 70.0 | ①③④⑤⑥⑦ |
骨化三醇 | 33 | 53.6 | 136.0 | 71.0 |
研究 | 国家 | 周期 (周) | 干预措施 | 样本量 | 平均年龄 (岁) | 收缩压 (mmHg) | 舒张压 (mmHg) | 结局指标 |
---|---|---|---|---|---|---|---|---|
Alborzi等[ | 美国 | 6 | 空白对照 | 8 | 68.4 | 未描述 | 未描述 | ①③ |
帕立骨化醇(1 μg/d) | 8 | 72.6 | ||||||
帕立骨化醇(2 μg/d) | 8 | 67.5 | ||||||
Fishbane等[ | 美国 | 24 | 安慰剂 | 27 | 60.8 | 未描述 | 未描述 | ①⑤⑥⑦ |
帕立骨化醇 | 28 | 55.0 | ||||||
de Zeeuw等[ | 美国 | 24 | 安慰剂 | 93 | 64.0 | 142.0 | 73.0 | ① |
帕立骨化醇(1 μug/d) | 93 | 64.0 | 142.0 | 73.0 | ||||
帕立骨化醇(2 μg/d) | 95 | 65.0 | 141.0 | 73.0 | ||||
Liu等[ | 中国 | 48 | 空白对照 | 24 | 36.3 | 118.3 | 73.8 | ②⑤⑥ |
骨化三醇 | 26 | 35.6 | 117.1 | 76.7 | ||||
殷勋等[ | 中国 | 24 | 缬沙坦 | 20 | 66.5 | 111.8 | 71.3 | ②⑤⑥⑦ |
骨化三醇 | 20 | 68.8 | 110.2 | 69.1 | ||||
Molina等[ | 西班牙 | 24 | 空白对照 | 51 | 67.4 | 130.5 | 72.8 | ①③④⑤⑥⑦ |
24 | 胆钙化醇 | 50 | 77.3 | 133.7 | 72.7 | |||
Wu等[ | 中国 | 24 | 空白对照 | 32 | 56.1 | 134.0 | 70.0 | ①③④⑤⑥⑦ |
骨化三醇 | 33 | 53.6 | 136.0 | 71.0 |
[1] |
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11): 825-830.
doi: 10.7326/0003-4819-158-11-201306040-00007 pmid: 23732715 |
[2] |
Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016[J]. Kidney Int, 2018, 94(3): 567-581.
doi: 10.1016/j.kint.2018.04.011 URL |
[3] |
Bökenkamp A. Proteinuria-take a closer look![J]. Pediatric nephrology (Berlin, Germany), 2020, 35(4): 533-541.
doi: 10.1007/s00467-019-04454-w URL |
[4] |
Huang Z, Wen Q, Zhou SF, et al. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome[J]. Cytokine, 2008, 42(2): 222-233.
doi: S1043-4666(08)00040-9 pmid: 18362077 |
[5] |
Li B, Chen K, Wang J, et al. Low-grade albuminuria is associated with high cardiovascular risk in CVD-free and normoalbuminuric Chinese adults: Results from the REACTION study[J]. J Diabetes, 2021, 13(8): 648-660.
doi: 10.1111/1753-0407.13152 pmid: 33389816 |
[6] |
Darlington O, Dickerson C, Evans M, et al. Costs and healthcare resource use associated with risk of cardiovascular morbidity in patients with chronic kidney disease: Evidence from a systematic literature review[J]. Adv Ther, 2021, 38(2): 994-1010.
doi: 10.1007/s12325-020-01607-4 pmid: 33432542 |
[7] |
Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects[J]. Physiol Rev, 2016, 96(1): 365-408.
doi: 10.1152/physrev.00014.2015 pmid: 26681795 |
[8] |
Jiang S, Zhang H, Li X, et al. Vitamin D/VDR attenuate cisplatin-induced AKI by down-regulating NLRP3/Caspase-1/GSDMD pyroptosis pathway[J]. J Steroid Biochem Mol Biol, 2021, 206: 105789.
doi: 10.1016/j.jsbmb.2020.105789 URL |
[9] |
Molina P, Górriz JL, Molina MD, et al. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled study[J]. Nephrol Dial Transplant, 2014, 29(1): 97-109.
doi: 10.1093/ndt/gft360 URL |
[10] |
Xu L, Wan X, Huang Z, et al. Impact of vitamin D on chronic kidney diseases in non-dialysis patients: A meta-analysis of randomized controlled trials[J]. PLoS One, 2013, 8(4): e61387.
doi: 10.1371/journal.pone.0061387 URL |
[11] |
Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial[J]. Hypertension, 2008, 52(2): 249-255.
doi: 10.1161/HYPERTENSIONAHA.108.113159 pmid: 18606901 |
[12] |
Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial[J]. Am J Kidney Dis, 2009, 54(4): 647-652.
doi: 10.1053/j.ajkd.2009.04.036 pmid: 19596163 |
[13] |
de Zeeuw D, Agarwal R, AMDahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes(VITAL study): A randomised controlled trial[J]. Lancet, 2010, 376(9752): 1543-1551.
doi: 10.1016/S0140-6736(10)61032-X pmid: 21055801 |
[14] |
Liu LJ, Lv JC, Shi SF, et al. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: A randomized controlled trial[J]. Am J Kidney Dis, 2012, 59(1): 67-74.
doi: 10.1053/j.ajkd.2011.09.014 pmid: 22019331 |
[15] |
Molina P, Górriz JL, Molina MD, et al. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled study[J]. Nephrol Dial Transplant, 2014, 29(1): 97-109.
doi: 10.1093/ndt/gft360 URL |
[16] | 殷勋, 水光兴, 桑栋, 等. 1, 25(OH)2D3延缓慢性肾衰竭进展的临床随机对照研究[J]. 中国中西医结合肾病杂志, 2014, 15(1):54-56. |
[17] |
Wu CC, Liao MT, Hsiao PJ, et al. Antiproteinuria effect of calcitriol in patients with chronic kidney disease and vitamin d deficiency: A randomized controlled study[J]. J Ren Nutr, 2020, 30(3):200-207.
doi: 10.1053/j.jrn.2019.09.001 URL |
[18] |
Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review[J]. JAMA, 2019, 322(13): 1294-1304.
doi: 10.1001/jama.2019.14745 pmid: 31573641 |
[19] |
Sharma S, Smyth B. From proteinuria to fibrosis: An update on pathophysiology and treatment options[J]. Kidney Blood Press Res, 2021, 46(4): 411-420.
doi: 10.1159/000516911 URL |
[20] |
Liu D, Lv LL. New understanding on the role of proteinuria in progression of chronic kidney disease[J]. Adv Exp Med Biol, 2019, 1165: 487-500.
doi: 10.1007/978-981-13-8871-2_24 pmid: 31399981 |
[21] |
Canney M, Barbour SJ, Zheng Y, et al. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy[J]. J Am Soc Nephrol, 2021, 32(2): 436-447.
doi: 10.1681/ASN.2020030349 pmid: 33514642 |
[22] |
Liu BC, Tang TT, Lv LL, et al. Renal tubule injury: A driving force toward chronic kidney disease[J]. Kidney Int, 2018, 93(3): 568-579.
doi: 10.1016/j.kint.2017.09.033 URL |
[23] |
Sanz AB, Ramos AM, Soler MJ, et al. Advances in understanding the role of angiotensin-regulated proteins in kidney diseases[J]. Expert Rev Proteomics, 2019, 16(1): 77-92.
doi: 10.1080/14789450.2018.1545577 URL |
[24] | Tuttle KR, Brosius FC 3rd, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation[J]. AAm J Kidney Dis, 2021, 77(1): 94-109. |
[25] |
Broek MVD, Smeets B, Schreuder MF, et al. The podocyte as a direct target of glucocorticoids in nephrotic syndrome[J]. Nephrol Dial Transplant, 2022, 37(10):1808-1815.
doi: 10.1093/ndt/gfab016 URL |
[26] |
Martínez-Arias L, Panizo S, Alonso-Montes C, et al. Effects of calcitriol and paricalcitol on renal fibrosis in CKD[J]. Nephrol Dial Transplant, 2021, 36(5): 793-803.
doi: 10.1093/ndt/gfaa373 URL |
[27] |
Namir Y, Cohen MJ, Haviv YS, et al. Vitamin D levels, vitamin D supplementation, and prognosis in patients with chronic kidney disease[J]. Clin Nephrol, 2016, 86(10): 165-1674.
doi: 10.5414/CN108796 URL |
[28] |
Manson JE, Cook NR, LeeI M, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease[J]. N Engl J Med, 2019, 380(1): 33-44.
doi: 10.1056/NEJMoa1809944 URL |
[1] | Wu Weijun, Chen Xiao, Wang Shaodan, Bu Laijun, Wu Xinchao, Yan Chenyang, Dong Gaiqin, Jiang Lijun, Wei Wenping. Analysis of screening data of urinalysis in 1973 students in Yangzhou [J]. Clinical Focus, 2023, 38(8): 702-705. |
[2] | Xiao Wangjing, Li Xinmeng, Lu Songling, Sun Xuehua. Efficacy and safety of repetitive transcranial magnetic stimulation treatment on central neurogenic dysphagia: A meta-analysis [J]. Clinical Focus, 2023, 38(7): 588-599. |
[3] | You Yi, Gao Shuqing, Xu Hao. Effect of enteral nutrition on postoperative clinical outcome of esophageal neoplasms: A meta-analysis [J]. Clinical Focus, 2023, 38(6): 485-492. |
[4] | Jiang Ji, Zhu Xiaogang, Jiang Shan, Dawa Zhaba, Cen Qiang. Risk factors of proteinuria in hypertensive people living at high altitude for generations [J]. Clinical Focus, 2023, 38(12): 1086-1090. |
[5] | Ke Mengting, Chen Wei. Meta-analysis of the antihypertensive effects of rosuvastatin [J]. Clinical Focus, 2023, 38(11): 965-971. |
[6] | Ruan Junwen, Zhou Jianrong, Liu Weiyou, Yuan Xiaoliang, Yan Hao. Meta-analysis of the efficacy and safety of dupilumab on the treatment of bronchial asthma [J]. Clinical Focus, 2023, 38(10): 869-877. |
[7] | Xi Hongmin, Yang Lijuan, Yin Xiangyun, Yang Ping, Ma Lili, Li Xianghong. Dynamic monitoring of blood 25 (OH) D level and its effect on pulmonary disease in very premature infants [J]. Clinical Focus, 2022, 37(8): 717-722. |
[8] | Wang Mengmeng, Wang Ying, Chen Zhaojing, Xu Xianrong, Yang Jun, Li Hongjuan. Effects of insulin aspart combined with vitamin D in treatment of blood glucose levels and perinatal complications of patients with gestational diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2021, 36(7): 581-586. |
[9] | Zhang Jingzhi, Liu Xiaolong, Xu Simao. Effects of Yoga on patients with neck pain: a meta-analysis [J]. Clinical Focus, 2021, 36(6): 485-490. |
[10] | Shao Na, Wang Shuo, Li Yao, Luo Xuemei, Tan Chuanmei. Relations between serum 25-(OH)D level and short stature in children [J]. Clinical Focus, 2021, 36(4): 353-356. |
[11] | Zhao Weifeng, Ma Chunyu. Correlation between 25-(OH)D3 and degree of coronary artery stenosis in patients with coronary heart disease [J]. Clinical Focus, 2021, 36(11): 981-985. |
[12] | Liu Yuanliang, Li Biao, Jiang Zuofeng, Zhu Youfeng, Zhang Shaoheng, Wang Yarong, Li Rongseng, Li Li. Efficacy and safety of half-dose versus standard-dose of tirofiban for percutaneous coronary intervention in elderly Chinese patients with acute coronary syndrome: a meta-analysis [J]. Clinical Focus, 2021, 36(11): 965-971. |
[13] | Cheng Xiangjuan, Wang Qiongkang, Li Jing. Therapeutic effect of vitamin D2 on type 2 diabetes complicated with cardiac autonomic neuropathy in different medication cycles [J]. Clinical Focus, 2020, 35(8): 711-713. |
[14] | Lin Xiaoxia, Ke Zhongling, Chen Yanhui, Chen Hui, Chen Xianrui. Meta analysis of the relationship between vitamin D levels and tic disorder [J]. Clinical Focus, 2020, 35(12): 1061-1066. |
[15] | Wang Jiangli1, Liu Maodong2, Chi Yanqing2, Zhang Yimin3, Li Ying2. Urine UbA52 and urine VDBP detection and significance in patients with diabetic nephropathy [J]. Clinical Focus, 2019, 34(6): 541-544. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||